William Blair Issues Positive Forecast for Insulet Earnings

Insulet Co. (NASDAQ:PODD) – Investment analysts at William Blair upped their Q4 2024 earnings per share (EPS) estimates for shares of Insulet in a research note issued on Monday, November 11th. William Blair analyst M. Andrew now forecasts that the medical instruments supplier will post earnings per share of $1.18 for the quarter, up from their previous forecast of $0.99. The consensus estimate for Insulet’s current full-year earnings is $3.11 per share. William Blair also issued estimates for Insulet’s Q1 2025 earnings at $0.83 EPS, Q2 2025 earnings at $0.84 EPS and FY2025 earnings at $3.91 EPS.

A number of other equities research analysts also recently issued reports on the stock. Raymond James upped their price target on shares of Insulet from $213.00 to $260.00 and gave the company an “outperform” rating in a research note on Monday, October 14th. BTIG Research upped their target price on shares of Insulet from $260.00 to $270.00 and gave the company a “buy” rating in a research report on Friday, November 8th. Sanford C. Bernstein began coverage on shares of Insulet in a research report on Wednesday, November 6th. They set an “outperform” rating and a $300.00 target price on the stock. Morgan Stanley upped their target price on shares of Insulet from $234.00 to $317.00 and gave the company an “overweight” rating in a research report on Monday. Finally, Piper Sandler upped their target price on shares of Insulet from $230.00 to $285.00 and gave the company an “overweight” rating in a research report on Tuesday, September 17th. Three equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $253.27.

Insulet Stock Down 0.2 %

Shares of PODD opened at $275.10 on Wednesday. The business’s 50 day simple moving average is $234.83 and its 200-day simple moving average is $206.03. Insulet has a 1 year low of $156.00 and a 1 year high of $279.40. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80. The stock has a market capitalization of $19.30 billion, a price-to-earnings ratio of 47.11, a price-to-earnings-growth ratio of 4.36 and a beta of 1.22.

Hedge Funds Weigh In On Insulet

Hedge funds have recently added to or reduced their stakes in the stock. QRG Capital Management Inc. bought a new position in Insulet in the 3rd quarter worth about $297,000. Diversified Trust Co grew its stake in Insulet by 90.9% in the 2nd quarter. Diversified Trust Co now owns 9,130 shares of the medical instruments supplier’s stock worth $1,842,000 after acquiring an additional 4,348 shares in the last quarter. Intech Investment Management LLC grew its stake in Insulet by 113.8% in the 1st quarter. Intech Investment Management LLC now owns 6,649 shares of the medical instruments supplier’s stock worth $1,140,000 after acquiring an additional 3,539 shares in the last quarter. Natixis bought a new position in Insulet in the 1st quarter worth about $3,610,000. Finally, Seven Eight Capital LP bought a new position in shares of Insulet during the first quarter valued at approximately $1,418,000.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.